Life Science Investing Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Consistent Results after Dosing with EP-104GI
Life Science Investing Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Life Science Investing Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
Life Science Investing Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
Life Science Investing First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis , Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI
Life Science Investing Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
life science investing Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
life science investing Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis
